


The Rethinking Clinical Trials (REaCT) program: a new frontier in Health Services Research

Mark Clemons^{1,2,3}, Lisa Vandermeer³, Angel Arnaout^{2,3,4}, John Hilton¹, Carol Stober³,
Marta Sienkiewicz³, Deanna Saunders³, Ahwon Jeong³, Brian Hutton^{1,2}, Dean Fergusson^{1,2}

¹ Department of Medicine, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Canada ² School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa
³ Cancer Research Group, Ottawa Hospital Research Institute, Ottawa, Canada ⁴ Department of Surgery, The Ottawa Hospital and the University of Ottawa, Ottawa, Canada

Purpose: Despite the increased incidence of cancer and the availability of more effective treatments, the number of patients enrolled in clinical trials is falling. A consequence of this is that decisions made in clinical practice will often have little or no high-quality supportive evidence. The Rethinking Clinical Trials (REaCT) program was created in 2014 to develop such evidence through a broad range of Health Services Research-related strategies. We reviewed the successes and challenges the program has faced.

Figure 1: Pragmatic Trials Initiative




Basulaiman B, Awan A, Fergusson D, Vandermeer L, Arnaout A, Hilton J, Hutton B, Joy A, Robinson A, Califaretti N, Stober C, Sienkiewicz M, Thavorn K, and Clemons M. Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Breast Cancer Res and Treatment 2019 (in press)

Table 2: REaCT Trials Portfolio

	Completed	Open and enrolling
Adjuvant Systemic Therapy	REaCT-TNBC (Hilton 2018)	REaCT-ZOL REaCT-Low Risk HER2 (pending REB)
Adjuvant Supportive Care	REaCT-G (Ibrahim, 2018) REaCT-G2 REaCT-TC (Hilton 2016 and Clemons 2018) REaCT-DEX (Hsu 2019, under review) REaCT-TAPS	REaCT-TC2 ILIAD
Palliative Supportive Care	REaCT-Mg REaCT-BTA	
Vascular Devices	REaCT-VA Her2+ REaCT-VA HER2-	
Surgery	REaCT-ADM	REaCT-NSQIP
Radiation		REaCT-RETT (pending REB)
Imaging	REaCT-EF	
Diagnostic Pathology Profiling	REaCT-MAGEE (Roberston 2018)	REaCT-Algorithm (pending REB)

Figure 2: Accrual of participants by REaCT Trial



Since its initiation, over 2000 participants have been enrolled in 15 REaCT Trials at 13 Canadian sites:

- The Ottawa Hospital Cancer Centre, Ottawa
- Cross Cancer Institute, Edmonton
- Cancer Centre South East, Kingston
- Grand River Regional Cancer Centre, Kitchener
- London Regional Cancer Program, London
- South Lake Regional Cancer Centre, Newmarket
- Northeast Cancer Centre, Sudbury
- Regional Cancer Centre Northwest, Thunder Bay
- Tom Baker Cancer Centre, Calgary
- Markham Stouffville Hospital, Markham
- Lakeridge Health, Oshawa
- UHN Toronto Western Hospital, Toronto
- Mount Sinai Hospital, Toronto

Conclusions: The REaCT program was devised to guide practice and to increase the availability of pragmatic clinical trials. While many challenges remain, future strategies will involve including more study sites, more tumour types and efforts to integrate novel information technology strategies.

Acknowledgements: We would like to acknowledge funding support from:

- CCSRI grant funding (ILIAD trial, Dr. Mark Clemons)
- CIHR—SPOR grant funding (REaCT infrastructure, Dr. Dean Fergusson)
- CCO funding provided by the Government of Ontario - CPQI grant funding (REaCT Program, 2017 and 2018, Dr Clemons)
- Donations to The Ottawa Hospital Foundation in support of the REaCT Program
- Funding and operational support made available through Canadian Cancer Clinical Trials Network (3CTN) that continues to foster the capability for conducting multicenter academic clinical trials at cancer centres across Canada.